BCL2L1 and osteosarcoma: Similarly to other sarcoma subtypes, some studies have focused on Bcl-xL and the sensitization of osteosarcoma cell lines to chemotherapy [108], with the use of WEHI-539 (a Bcl-xL selective BH3 mimetic) obtaining a potent increase in apoptosis even with low doses of doxorubicin [109].